SOURCE-LINKED STUDY SUMMARY
CagriSema vs Semaglutide: 32-Week Phase 2 Results
PED EVIDENCE INTERPRETATION
Did CagriSema outperform both components?
In this 92-person phase 2 trial, weight fell 15.6% with CagriSema versus 5.1% with semaglutide at 32 weeks. The primary HbA1c difference versus semaglutide was statistically uncertain, so the weight result should not stand in for every outcome. [1]
- Design
- Double-blind randomized active-controlled trial; 92 participants
- Population
- Type 2 diabetes, BMI ≥27; metformin with or without an SGLT2 inhibitor
- Comparison
- Weekly subcutaneous cagrilintide plus semaglutide vs either alone; each component escalated to 2.4 mg
- Duration
- 32 weeks
The evidence at a glance
OUR READING OF THE EVIDENCE
What this changes
The weight result supports testing the combination in larger and longer trials. It should be reported alongside the uncertain primary-endpoint comparison with semaglutide. [1]
What it does not establish
With approximately 30 people per arm, similar adverse-event percentages cannot establish equivalent safety or exclude uncommon harms. This is not a comparison with tirzepatide. [1]
Put it in context
Sources and transparency
Funded by Novo Nordisk. Abstract-based interpretation; not an independent assessment of all adverse events or methodological quality. [1]
Questions this study helps answer
Was CagriSema better on the primary outcome?
Versus semaglutide, the HbA1c difference was −0.4 percentage points, with a 95% confidence interval of −0.8 to 0.0 and P=0.075. That comparison did not meet the conventional 0.05 threshold. [1]
Did the trial compare CagriSema with tirzepatide?
No. Its three groups were CagriSema, semaglutide and cagrilintide. It cannot establish superiority over tirzepatide. [1]
Original compact summary and study details
- What was studied
- A 32-week, double-blind phase 2 trial randomized adults with type 2 diabetes to weekly CagriSema, semaglutide or cagrilintide. The primary outcome was change in HbA1c.
- Who / model studied
- The trial included 92 adults with type 2 diabetes and BMI of at least 27 who used metformin, with or without an SGLT2 inhibitor: 31 received CagriSema, 31 semaglutide and 30 cagrilintide.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- HbA1c fell 2.2 percentage points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide. CagriSema was superior to cagrilintide, but not semaglutide, for the primary outcome. Weight fell 15.6%, versus 5.1% and 8.1%; gastrointestinal events were usually mild or moderate.
- Limitations & context
- This was a small phase 2 trial with 32 weeks of follow-up; the authors called for larger, longer phase 3 studies.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(23)01163-7